Earlier this week our President and CEO, Gilmore ONeill, joined Let’s Talk About That with Anirvan Ghosh for a thoughtful discussion on his journey into biotechnology, the future of in vivo gene editing in treating serious diseases, and EDIT-401, an experimental, potential best-in-class, one-time therapy that has achieved an unprecedented ≥90% mean LDL cholesterol (LDL-C) reduction in non-human primates. To listen to the full episode, click here: https://bit.ly/4k3RHko For more details on EDIT-401 visit our recent presentation: https://bit.ly/3YZspKC #invivogeneediting #biotechleadership
I recently joined Anirvan Ghosh on the Let’s Talk About That podcast to discuss my journey and the exciting advances underway at Editas Medicine, as we seek to leverage the power of in vivo gene editing to create transformative medicines for serious diseases. This includes the development of EDIT-401, an experimental, potential best-in-class, one-time therapy that has achieved an unprecedented ≥90% mean LDL cholesterol (LDL-C) reduction in non-human primates. I was delighted to join and engage in a deep conversation around the science behind our technology and discuss the considerations that led to our pursuit of LDL-R upregulation to significantly reduce LDL-C levels. Listen to the full episode here: https://bit.ly/4k3RHko For more details on EDIT-401 visit our recent presentation: https://bit.ly/3YZspKC #genediting #biotech